机器人辅助根治性前列腺切除术后下尿路症状改善:对生存管理、治疗选择与患者咨询的意义
基于2009年1月至2017年1月8年间1917例连续机器人辅助根治性前列腺切除术(RARP)的前瞻性数据库,分析其中1470例数据完整患者术前与术后12个月的国际前列腺症状评分(IPSS)和生活质量(QoL)评分变化。结果显示57%患者IPSS改善,76%术后IPSS≤7,41%患者QoL改善,术前严重下尿路症状(IPSS 20-35)患者中90.3%在术后1年下尿路症状获临床改善。作者认为多数患者术后12个月整体下尿路症状和QoL改善,术前IPSS高者获益最大,需进一步分析具体IPSS领域并延长随访。
要点
- RARP术后12个月57%患者IPSS改善,76%患者IPSS≤7
- 术前严重下尿路症状(IPSS 20-35)患者中90.3%术后1年下尿路症状临床改善
- 41%患者报告QoL改善,术前IPSS高者获益最大
核心结论
- RARP术后12个月多数患者整体下尿路症状和QoL改善,术前IPSS高者获益最大。
- 该结果对接受前列腺癌积极治疗男性的治疗选择和术前咨询有参考意义。
- 作者指出需进一步分析具体IPSS领域并延长随访。
研究设计与样本
- 评估RARP术后下尿路症状(LUTS)和生活质量(QoL)变化的研究。
- 采用2009年1月至2017年1月8年间1917例连续RARP的前瞻性数据库。
- 收集术前年龄、前列腺特异性抗原(PSA)、体质指数(BMI)、IPSS和QoL评分,比较基线(术前)与术后12个月IPSS和QoL评分。
- 1917例RARP患者中1470例数据完整者纳入分析。
- 纳入患者平均±标准差年龄62(±6.7)岁、前列腺重量51(±17.6)g、BMI 28 kg/m2。
主要发现
- 57%患者报告IPSS评分改善,76%患者术后IPSS≤7。
- 41%患者报告QoL改善。
- 术前严重LUTS(IPSS 20-35)患者中90.3%在RARP术后1年下尿路症状获临床改善。
- 本研究RARP术后平均IPSS低于现有放疗后文献报告值,尤其在基线中重度LUTS(IPSS≥8)患者中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步分析具体IPSS领域并延长随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess changes in lower urinary tract symptoms (LUTS) and quality of life (QoL) after robot-assisted radical prostatectomy (RARP). PATIENTS AND METHODS: A prospectively curated database of 1917 consecutive RARPs undertaken over an 8-year period from January 2009 to January 2017 was assessed. Preoperative information including age, prostate-specific antigen (PSA) level, body mass index (BMI), International Prostate Symptom Score (IPSS) and QoL score was collected, with IPSS and QoL score compared between baseline (preoperatively) and 12 months post-surgery. RESULTS: Of the 1917 patients who underwent RARP, 1470 with complete data were included in the analysis. Their mean ± sd age, prostate weight and BMI were 62 (±6.7) years, 51 (±17.6) g, and 28 kg/m2 , respectively. Overall, 57% of patients reported an improved IPSS score, whilst 76% reported an IPSS of ≤7 postoperatively. A total of 41% of patients reported an improved QoL and 90.3% of patients with severe preoperative LUTS (IPSS 20-35) demonstrated clinically improved LUTS at 1 year post RARP. The post-RARP mean IPSS in the present study was lower than those reported in the existing post-radiotherapy literature, especially in patients with moderate to severe baseline LUTS (IPSSs ≥ 8). CONCLUSIONS: At 12 months post RARP, most patients reported improved overall LUTS and QoL, with the greatest benefit seen in those patients with a high pre-RARP IPSS. This has implications for treatment selection and preoperative counselling in men being offered active treatment for their prostate cancer. Further analyses of specific IPSS domains and longer follow-up are needed.
引用
- Ahn T, Roberts MJ, Strahan A, et al. Improved lower urinary tract symptoms after robot-assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling. BJU Int. 2019. PMID: 31012991. doi:10.1111/bju.14717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。